|
|
|
|
|
|
|
|
Delaware
|
|
001-37797
|
|
27-3948465
|
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock $0.0001 Par Value
|
INNT
|
The Nasdaq Stock Market LLC
|
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
|
|
Nominees
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
Lorin K. Johnson, Ph.D.
|
|
15,569,554
|
|
930,743
|
|
7,211,439
|
Roy Proujansky, M.D.
|
|
15,789,612
|
|
710,685
|
|
7,211,439
|
For
|
|
Against
|
|
Abstain
|
22,923,154
|
|
788,043
|
|
539
|
|
|
|
|
|
|
|
|
|
|
|
Innovate Biopharmaceuticals, Inc.
|
||
|
|
|
|
|||
Date: May 31, 2019
|
|
|
|
By:
|
|
/s/ Jay P. Madan
|
|
|
|
|
|
|
Jay P. Madan
|
|
|
|
|
|
|
President and Chief Business Officer
|